Rough timeline update on first patient:
Receive dose days 1 & 15
Treatment repeats every 28 days for 3 cycles.
my calculations:
CYCLE 1
13th April, day 1 - dose 1
27th April, day 15 - dose 2 *(currently just had)*
CYCLE 2
10th May, day 28 or day 1 - dose 3
24th May, day 15 - dose 4
CYCLE 3
6th June, day 28 or day 1 - dose 5
20th June, day 15 - dose 6
3rd July, day 28 - Finish Patient 1 cohort 2.
We received news of patient 2 being dosed in the first cohort, roughly 35 days (which includes the 28 day safety window) after patient 1 had completed their 2nd dose of CYCLE 1.
So if they keep in check with this, we should hopefully get an update of the 2nd patient being dosed in cohort 2 late May.
With all fingers crossed, hope we have even better data on infiltration and replication of the virus within the tumour and even shrinking of tumour at this higher dose.
To all LTH/SH enjoy the waiting game and to all the patients and their families, all the very best.
- Forums
- ASX - By Stock
- IMU
- Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc
Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc, page-77
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.2¢ |
Change
-0.002(2.83%) |
Mkt cap ! $386.7M |
Open | High | Low | Value | Volume |
5.3¢ | 5.3¢ | 5.1¢ | $435.8K | 8.368M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
58 | 6938638 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 2773928 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
58 | 6938638 | 0.051 |
89 | 5679696 | 0.050 |
19 | 3112205 | 0.049 |
17 | 1314838 | 0.048 |
5 | 237373 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 2773928 | 18 |
0.053 | 1058770 | 12 |
0.054 | 1629278 | 4 |
0.055 | 1986094 | 15 |
0.056 | 890463 | 10 |
Last trade - 12.08pm 12/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |